WilmerHale represented the underwriters in the initial public offering of 10,000,000 shares of common stock of Amylyx Pharmaceuticals, a clinical-stage biopharmaceutical company, at an initial public offering price of $19.00 per share. Amylyx granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering priced on January 6, 2022, and closed on January 11, 2022. The gross proceeds to the company were $190 million.

The WilmerHale team advising the underwriters consisted of Lisa Firenze, Jeffries Oliver-Li, Ryan Brewer, Chris Gravallese, Bruce Manheim, Colleen Superko and Heidi Treiber.

For more information, read Amylyx Pharmaceuticals’ press release.